Jun 2021

FRANCE 24 English (@France24_en) Tweeted: 🇺🇸💊#US regulators approved #Biogen Inc’s #aducanumab as the 1st treatment to attack a likely cause of #Alzheimer’s disease.

🎤@AndrewJDoig1, professor of biochemistry, explains how the drug works – and why its results may be “stunning” for Alzheimer’s patients⤵️

Jun 2021

Controversial Alzheimer’s drug paves the way for more advances

Aducanumab, a new drug for Alzheimer’s disease, and the first in nearly 20 years, has been approved in the United States. In spite of mixed evidence over its efficacy, the desperate need for treatment makes it likely that governments across the world will also strive to make the drug available. Despite the concerns, University of Manchester biochemist Professor Andrew Doig, reasons that the drug is a positive step and will pave the way for even greater advances. Professor Doig is a board member of PharmaKure, a University of Manchester spin-out company which is involved in developing, commercialising and repositioning drugs for the treatment of Alzheimer’s, Parkinson’s and other diseases.

He said: “Aducanumab works by breaking down the amyloid-β protein clumps that are present in the brains of Alzheimer’s victims, using antibodies. However, we don’t yet know whether removing amyloid-β can reverse the cognitive effects of Alzheimer’s, such as loss of short-term memory. In addition, the treatment is likely to be very expensive and may have unwanted side effects.

“Our company, PharmaKure, has a unique approach to identify off-label compounds that also break down amyloid-β clumps, but with few side effects and a cost-effective price. We are excited about Aducanumab as it paves the way for more effective drugs for Alzheimer’s that tackle the root cause of the disease. We hope that effective treatments for this debilitating disease will be available for all, sooner, rather than later.”

Prof Doig is  available for comment

Nov 2020

Greenbank Capital Announces Letter of Intent to Acquire Stake in, and Provide Merchant Banking Services to PharmaKure, the pioneer of an important and potentially revolutionary treatment for Alzheimer’s.